Company Profile
Lantern PharmaAI Stock Price, News & Analysis
- Ticker:
- LTRN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.79 USD (+1.45%)
Close
Last updated: July 27, 2026
47.7M USD
Market cap
Why the stock is moving
As of Jul 27, 2026, LTRN closed up 1.45% at $2.79. No new same-company headline was identified in the current news window.
Company overview
Business overview
Lantern Pharma is a technology-enabled oncology company focused on AI-assisted drug discovery and precision cancer medicine. Its platform combines computational tools with targeted oncology development.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Lantern sits at the intersection of AI and oncology biotechnology.
Business Model Characteristics
The company depends on platform adoption, clinical progress, and the translation of AI-driven discovery into pipeline value.
Position Within the Biotechnology Landscape
Lantern is a hybrid AI-oncology name whose stock depends on both platform credibility and drug-development progress.
Future catalysts
Lantern’s catalysts are its AI-driven oncology discovery platform and any partnered or internal pipeline update. The company needs evidence that the platform is producing more than just tools.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
LEGN · Source: Legend Biotech Corporation
- 03
- 04
- 05
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Lantern PharmaAI (LTRN)?
Lantern PharmaAI (LTRN) most recently closed at 2.79 USD, a +1.45% move versus the previous session.
What is the market cap of Lantern PharmaAI (LTRN)?
Lantern PharmaAI currently has a market capitalization of 47.7M USD on BioPharmSignal.
What does Lantern PharmaAI do?
Lantern Pharma is a technology-enabled oncology company focused on AI-assisted drug discovery and precision cancer medicine. Its platform combines computational tools with targeted oncology development.
On which exchange is LTRN stock listed?
Lantern PharmaAI (LTRN) is associated with NASDAQ, United States, Biopharma.
What is Lantern?
Lantern’s catalysts are its AI-driven oncology discovery platform and any partnered or internal pipeline update.
Which conditions is Lantern PharmaAI targeting with Lantern?
Lantern PharmaAI is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Lantern PharmaAI describe recent progress with Lantern?
Lantern’s catalysts are its AI-driven oncology discovery platform and any partnered or internal pipeline update.
What is Pharma?
Lantern Pharma is a technology-enabled oncology company focused on AI-assisted drug discovery and precision cancer medicine.